{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:44:09Z","timestamp":1791110649603,"version":"4.1.0"},"reference-count":45,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,16]]},"DOI":"10.20945\/2359-3997000000560","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:25:40Z","timestamp":1668687940000},"page":"717-723","source":"Crossref","is-referenced-by-count":9,"title":["Long-term consequences of osteoporosis therapy with denosumab"],"prefix":"10.20945","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-0742","authenticated-orcid":false,"given":"Francisco","family":"Bandeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-0664","authenticated-orcid":false,"given":"Lucian Batista de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2617","authenticated-orcid":false,"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"8","key":"key20221117072530_B1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20221117072530_B2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20221117072530_B3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwi\u0144ski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"key20221117072530_B4","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483-92.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key20221117072530_B5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"key20221117072530_B6","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829-35.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"key20221117072530_B7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471-9.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221117072530_B8","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","article-title":"Denosumab for dialysis patients with osteoporosis: A cohort study","volume":"10","author":"Kunizawa","year":"2020","unstructured":"Kunizawa K, Hiramatsu R, Hoshino J, Mizuno H, Ozawa Y, Sekine A, et al. Denosumab for dialysis patients with osteoporosis: A cohort study. Sci Rep. 2020;10(1):2496.","journal-title":"Sci Rep"},{"issue":"1","key":"key20221117072530_B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"5","key":"key20221117072530_B10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1210\/jc.2018-02236","article-title":"Comparison of denosumab and bisphosphonates in patients with osteoporosis: A meta-analysis of randomized controlled trials","volume":"104","author":"Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, et al. Comparison of denosumab and bisphosphonates in patients with osteoporosis: A meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2019;104(5):1753-65.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20221117072530_B11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: Different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011;48(4):677-92.","journal-title":"Bone"},{"issue":"10169","key":"key20221117072530_B12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364-76.","journal-title":"Lancet"},{"issue":"1","key":"key20221117072530_B13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","article-title":"Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates","volume":"31","author":"Miller","year":"2020","unstructured":"Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwi\u0144ski E, Bone HG, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020;31(1):181-91.","journal-title":"Osteoporos Int"},{"issue":"13","key":"key20221117072530_B14","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2022.37.e68","article-title":"Comparison of denosumab and zoledronic acid in postmenopausal women with osteoporosis: Bone mineral density (BMD) and Trabecular Bone Score (TBS)","volume":"37","author":"Kang","year":"2022","unstructured":"Kang T, Park SY, Lee SH, Park JH, Suh SW. Comparison of denosumab and zoledronic acid in postmenopausal women with osteoporosis: Bone mineral density (BMD) and Trabecular Bone Score (TBS). J Korean Med Sci. 2022;37(13):e68.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"key20221117072530_B15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: A noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: A noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014;29(3):518-30.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"key20221117072530_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis \u2013 2020 update","volume":"26","author":"Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis \u2013 2020 update. Endocr Pract. 2020;26(Suppl 1):1-46.","journal-title":"Endocr Pract"},{"issue":"10","key":"key20221117072530_B17","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res. 2010;25(10):2256-65.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221117072530_B18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10067-005-1132-7","article-title":"Transiliac bone biopsy in osteoporosis: Frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years","volume":"25","author":"Kann","year":"2006","unstructured":"Kann PH, Pf\u00fctzner A, Delling G, Schulz G, Meyer S. Transiliac bone biopsy in osteoporosis: Frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years. Clin Rheumatol. 2006;25(1):30-4.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"key20221117072530_B19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00774-020-01153-7","article-title":"RANKL as a target for the treatment of osteoporosis","volume":"39","author":"Matsumoto","year":"2021","unstructured":"Matsumoto T, Endo I. RANKL as a target for the treatment of osteoporosis. J Bone Miner Metab. 2021;39(1):91-105.","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"key20221117072530_B20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jbmr.3901","article-title":"HR-pQCT measures of bone microarchitecture predict fracture: Systematic review and meta-analysis","volume":"35","author":"Mikolajewicz","year":"2020","unstructured":"Mikolajewicz N, Bishop N, Burghardt AJ, Folkestad L, Hall A, Kozloff KM, et al. HR-pQCT measures of bone microarchitecture predict fracture: Systematic review and meta-analysis. J Bone Miner Res. 2020;35(3):446-59.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"key20221117072530_B21","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jbmr.2855","article-title":"Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis","volume":"31","author":"Zebaze","year":"2016","unstructured":"Zebaze R, Libanati C, McClung MR, Zanchetta JR, Kendler DL, H\u00f8iseth A, et al. Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis. J Bone Miner Res. 2016;31(10):1827-34.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"key20221117072530_B22","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s00198-017-4140-y","article-title":"Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis","volume":"28","author":"McClung","year":"2017","unstructured":"McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, et al. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporos Int. 2017;28(10):2967-73.","journal-title":"Osteoporos Int"},{"issue":"6","key":"key20221117072530_B23","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00520-020-05855-6","article-title":"Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: A systematic review","volume":"29","author":"Querrer","year":"2021","unstructured":"Querrer R, Ferrare N, Melo N, Stefani CM, Dos Reis PED, Mesquita CRM, et al. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: A systematic review. Support Care Cancer. 2021;29(6):2811-20.","journal-title":"Support Care Cancer"},{"issue":"6","key":"key20221117072530_B24","first-page":"664","article-title":"Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis \u2013 A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso)","volume":"64","author":"Madeira","year":"2021","unstructured":"Madeira M, Rocha AC, Moreira CA, Aguiar \u00c1MM, Maeda SS, Cardoso AS, et al. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis \u2013 A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). Arch Endocrinol Metab. 2021;64(6):664-72.","journal-title":"Arch Endocrinol Metab"},{"issue":"9","key":"key20221117072530_B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/JAMMR\/2017\/34007","article-title":"Subclinical oral bisphosphonate-related osteonecrosis of the jaw: Systematic review of the literature and an additional case","volume":"22","author":"Vasconcelos","year":"2017","unstructured":"Vasconcelos SP, Lemos ALP, Bandeira F. Subclinical oral bisphosphonate-related osteonecrosis of the jaw: Systematic review of the literature and an additional case. JAMMR. 2017;22(9):1-19.","journal-title":"JAMMR"},{"issue":"6","key":"key20221117072530_B26","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","unstructured":"Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J Clin Endocrinol Metab. 2019;104(6):2443-52.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key20221117072530_B27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","unstructured":"Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010;141(11):1365-70.","journal-title":"J Am Dent Assoc"},{"issue":"2","key":"key20221117072530_B28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jbmr.4472","article-title":"Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis","volume":"37","author":"Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, H\u00e4uselmann H, et al. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. 2022;37(2):340-8.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20221117072530_B29","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. Zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. Zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25(3):e326-36.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"1","key":"key20221117072530_B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20221117072530_B31","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: A systematic review and recommendations from the European calcified tissue society","volume":"105","author":"van de Laarschot","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Gua\u00f1abens N, et al. Medical management of patients after atypical femur fractures: A systematic review and recommendations from the European calcified tissue society. J Clin Endocrinol Metab. 2020;105(5):1682-99.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20221117072530_B32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00774-014-0617-3","article-title":"Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: A comparison between treatment with and without teriparatide","volume":"33","author":"Miyakoshi","year":"2015","unstructured":"Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: A comparison between treatment with and without teriparatide. J Bone Miner Metab. 2015;33(5):553-9.","journal-title":"J Bone Miner Metab"},{"key":"key20221117072530_B33","doi-asserted-by":"crossref","first-page":"115287","DOI":"10.1016\/j.bone.2020.115287","article-title":"Favorable skeletal benefit\/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed","volume":"134","author":"Ferrari","year":"2020","unstructured":"Ferrari S, Lewiecki EM, Butler PW, Kendler DL, Napoli N, Huang S, et al. Favorable skeletal benefit\/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. Bone. 2020;134:115287.","journal-title":"Bone"},{"issue":"9","key":"key20221117072530_B34","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: A retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O; Swiss Denosumab Study Group. Fractures after denosumab discontinuation: A retrospective study of 797 cases. J Bone Miner Res. 2021;36(9):1717-28.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20221117072530_B35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CP203361","article-title":"Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate","volume":"57","author":"Bandeira","year":"2019","unstructured":"Bandeira F, Torres G, Bandeira E, Duarte MB, N\u00f3brega AM, Bandeira L. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate. Int J Clin Pharmacol Ther. 2019;57(3):163-6.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"key20221117072530_B36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00223-020-00785-1","article-title":"Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation","volume":"108","author":"Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S, et al. Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation. Calcif Tissue Int. 2021;108(5):587-94.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"key20221117072530_B37","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone Mineral Density After Transitioning From Denosumab to Alendronate","volume":"105","author":"Kendler","year":"2020","unstructured":"Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, et al. Bone Mineral Density After Transitioning From Denosumab to Alendronate. J Clin Endocrinol Metab. 2020;105(3):e255-64.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20221117072530_B38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","volume":"30","author":"Lamy","year":"2019","unstructured":"Lamy O, Fern\u00e1ndez-Fern\u00e1ndez E, Monjo-Henry I, Stoll D, Aubry-Rozier B, Benavent-N\u00fa\u00f1ez D, et al. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos Int. 2019;30(5):1111-5.","journal-title":"Osteoporos Int"},{"issue":"7","key":"key20221117072530_B39","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Shi Y, et al. Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus. 2021;5(7):e10512.","journal-title":"JBMR Plus"},{"issue":"4","key":"key20221117072530_B40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jocd.2021.01.006","article-title":"Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation","volume":"24","author":"Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Trovas G, Yavropoulou MP, Tournis S. Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation. J Clin Densitom. 2021;24(4):591-6.","journal-title":"J Clin Densitom"},{"issue":"4","key":"key20221117072530_B41","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3803\/EnM.2021.1193","article-title":"Preventing rebound-associated fractures after discontinuation of denosumab therapy: A position statement from the health insurance committee of the Korean Endocrine Society","volume":"36","author":"Kim","year":"2021","unstructured":"Kim BK, Kim CH, Min YK. Preventing rebound-associated fractures after discontinuation of denosumab therapy: A position statement from the health insurance committee of the Korean Endocrine Society. Endocrinol Metab (Seoul). 2021;36(4):909-11.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"9999","key":"key20221117072530_B42","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-55.","journal-title":"Lancet"},{"key":"key20221117072530_B43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, et al. Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11-7.","journal-title":"Bone"},{"issue":"6","key":"key20221117072530_B44","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291-6.","journal-title":"J Bone Miner Res"},{"key":"key20221117072530_B45","article-title":"Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020:dgaa756.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:26:17Z","timestamp":1668687977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/long-term-consequences-of-osteoporosis-therapy-with-denosumab\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11,16]]}},"alternative-id":["10.20945\/2359-3997000000560"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000560","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}